Your Patient Can't Find Brilinta — What Can You Do?

Few things are more frustrating for a prescriber than learning that a patient with acute coronary syndrome or coronary artery disease has gone days without their antiplatelet medication because they couldn't find it at their pharmacy. Given Brilinta's (Ticagrelor's) FDA boxed warning about the risk of premature discontinuation, this isn't just an inconvenience — it's a clinical emergency.

This guide provides actionable steps your practice can take to help patients find Brilinta or generic Ticagrelor in stock, navigate access barriers, and maintain the uninterrupted therapy that their cardiovascular outcomes depend on.

Current Availability Landscape

As of early 2026, the Brilinta/Ticagrelor supply picture is generally favorable but uneven:

• Not in shortage: Neither brand Brilinta nor generic Ticagrelor is listed on the FDA drug shortage database
• Multiple generic manufacturers: Alembic, Novadoz, Ascend, Teva, and Hisun Pharmaceuticals all produce generic Ticagrelor (60 mg and 90 mg)
• Pharmacy-level gaps persist: Individual pharmacies may not stock Ticagrelor consistently, particularly low-volume locations
• Brand vs. generic confusion: Some patients report being told their pharmacy is "out of Brilinta" when the pharmacy actually stocks generic Ticagrelor under a different manufacturer name

For detailed context on why patients struggle to find this medication, see the companion patient guide: Why Is Brilinta So Hard to Find?

Why Patients Can't Find Their Medication

Understanding the root causes helps your team troubleshoot effectively:

Pharmacy Inventory Management

Chain pharmacies use automated inventory systems that stock medications based on local demand. A pharmacy that fills only a few Ticagrelor prescriptions per month may carry minimal or no stock. When that single monthly patient arrives, the pharmacy needs to order — which can take 1–3 business days.

Generic Transition Disruption

The mid-2025 launch of generic Ticagrelor triggered widespread pharmacy restocking decisions. Many pharmacies dropped brand Brilinta but hadn't yet established reliable generic supply chains. While this transition is mostly complete, pockets of disruption remain.

Insurance and Formulary Barriers

Even when the medication is physically on the shelf, patients may encounter:

• Prior authorization requirements (especially for brand Brilinta when generic is available)
• Step therapy mandates requiring a trial of Clopidogrel first
• Quantity limits that don't align with prescribed doses
• NDC blocks on specific manufacturers

What Providers Can Do: 5 Actionable Steps

Step 1: Prescribe by Generic Name

Write prescriptions for "Ticagrelor" rather than "Brilinta" unless there's a specific reason to require the brand. This allows pharmacists to fill with whichever generic manufacturer they have in stock, dramatically increasing the chance of same-day fill.

If a patient specifically needs brand Brilinta (rare), indicate "DAW" (dispense as written) — but understand this may reduce availability and increase cost.

Step 2: Use Medfinder to Locate Stock

Train your front desk and care coordination staff to use Medfinder for Providers when patients call reporting they can't fill their prescription. Medfinder provides real-time pharmacy stock information, allowing your team to direct the patient to a specific pharmacy that has Ticagrelor available.

This single step can reduce "I can't find my medication" calls from a 30-minute problem to a 2-minute solution.

Step 3: Proactively Discuss Generics at Discharge and Follow-Up

Many patients don't know that generic Ticagrelor exists or that it's the same medication as Brilinta. During discharge planning or follow-up visits:

• Explain that generic Ticagrelor is FDA-approved and therapeutically equivalent to Brilinta
• Let them know it may look different (different pill color, shape, markings) but works the same way
• Mention that the generic typically costs $30–$100 per month with a discount card compared to $450–$665 for brand Brilinta

Step 4: Keep Samples and Bridge Supplies

Maintaining a small supply of Ticagrelor samples in your office can bridge patients through availability gaps. A 7–14 day supply gives the patient and pharmacy enough time to locate and order the medication without interrupting therapy.

Document any sample dispensing in the patient's chart and ensure follow-up to confirm the prescription was ultimately filled.

Step 5: Streamline Prior Authorization Workflows

If your patient's insurer requires prior authorization for Ticagrelor, having a template ready can speed the process:

• Include the specific FDA-approved indication (ACS, post-MI CAD, or acute ischemic stroke)
• Reference the PLATO or THEMIS trial data showing Ticagrelor's benefit over Clopidogrel when relevant
• Include CYP2C19 genotype data if available (demonstrates medical necessity when step therapy requires Clopidogrel trial first)
• Note any intolerance or contraindication to Clopidogrel

When to Consider Alternatives

If a patient truly cannot access Ticagrelor despite the steps above, consider these alternatives based on clinical context:

• Clopidogrel (Plavix): Most common alternative. Widely available, very affordable ($4–$15/month). Less potent; affected by CYP2C19 polymorphisms. Consider genetic testing before switching.
• Prasugrel (Effient): More potent platelet inhibition. Avoid in patients ≥75 years, <60 kg, or with history of stroke/TIA. Generic available at $15–$50/month.

For detailed clinical comparison, see Alternatives to Brilinta.

Critical reminder: Any change in antiplatelet therapy for a post-ACS or post-PCI patient warrants careful clinical assessment. The switch should be documented and the patient should understand the change.

Workflow Tips for Your Practice

Integrating medication access support into your practice workflow doesn't have to be burdensome. Consider these approaches:

At Discharge (Inpatient/Procedural)

• Confirm the patient's preferred pharmacy stocks Ticagrelor before discharge
• Send the e-prescription to that specific pharmacy
• Provide a 7-day supply of samples as a bridge if pharmacy confirmation isn't possible
• Include pharmacy access information in discharge instructions

At Follow-Up Visits

• Ask patients: "Are you having any trouble getting your Ticagrelor filled?"
• Review their current cost and suggest generic if they're still on brand
• Update the prescription to generic if appropriate

When Patients Call

• Have staff check Medfinder for nearby pharmacies with stock
• Offer to call in the prescription to an alternate pharmacy
• If no stock is available locally, consider a mail-order pharmacy option

Final Thoughts

Brilinta (Ticagrelor) is a guideline-recommended antiplatelet therapy for some of the most high-risk cardiovascular patients in your practice. Premature discontinuation carries life-threatening consequences. As providers, we have both the tools and the responsibility to help patients maintain uninterrupted access.

The generic transition has made Ticagrelor more affordable than ever. By prescribing generically, using stock-checking tools like Medfinder, and building medication access into your workflow, you can prevent the all-too-common scenario of a patient going without their antiplatelet therapy because of a pharmacy stocking issue.

For additional provider resources, including cost and savings information to share with patients, see our guide on how to help patients save money on Brilinta.